Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P40926

UPID:
MDHM_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P40926; A8K414; B2RE78; B4DE44; E9PDB2; O43682

BACKGROUND:
Malate dehydrogenase, mitochondrial, functions as a critical enzyme in the citric acid cycle, a key metabolic pathway that provides energy in the form of ATP. By catalyzing the conversion of malate into oxaloacetate, it not only participates in energy production but also in the regulation of the metabolic flux within the mitochondria, highlighting its importance in cellular metabolism.

THERAPEUTIC SIGNIFICANCE:
Given its association with Developmental and Epileptic Encephalopathy 51, a condition marked by early-onset, severe epilepsy and developmental challenges, the study of Malate dehydrogenase, mitochondrial, is of paramount importance. Insights into its function and dysfunction could lead to novel therapeutic approaches, potentially transforming the management of DEE51 and improving patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.